Articles, Explainers, Milestones
| 6 min read
Network biology and graph algorithms are reshaping how scientists find and rank new drug targets.
By combining organoid biology with precision automation, researchers developed a miniaturized organoid screening platform that could help speed personalized cancer treatment testing.
By combining organoid biology with precision automation, researchers developed a miniaturized organoid screening platform that could help speed personalized cancer treatment testing.
| 7 min read
AlphaFold is the most significant structural biology tool in a generation. Whether it has changed drug discovery at the same scale is a more nuanced question, and the honest answer separates real impact from hype.
| 6 min read
What genomic, proteomic, and transcriptomic data integration actually delivers for drug target discovery.
| 8 min read
Generative models can now design novel drug-like molecules on demand. What they generate reliably, and what medicinal chemists still have to fix, is the real story.
| 9 min read
How genomics, knowledge graphs, and prioritization models are reshaping AI target identification.
| 8 min read
AI is now embedded across the drug discovery pipeline. This guide maps the full arc, where the technology delivers, where it still falls short, and what the science actually shows.
| 5 min read
High-throughput screening has always been about speed and volume. As assays grow more biologically complex, the harder question is whether the data they generate can actually be trusted at scale.
| 9 min read
What if you could cut your seed train by an entire stage and still hit your target inoculation density? N-1 perfusion makes it possible.
| 9 min read
Is continuous manufacturing actually cheaper, or just faster? Here is the math.
| 8 min read
Handoffs kill timelines. Here is why end-to-end CDMOs are winning the race to the clinic.
